...
search icon
crsp-img

Crispr Therapeutics AG, Common Stock

CRSP

NMQ

$42.04

+$0.83

(2.01%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.65B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.61M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.66
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$36.52 L
$91.1 H
$42.04

About Crispr Therapeutics AG, Common Stock

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRSPSectorS&P500
1-Week Return-4.95%2.26%-1.3%
1-Month Return8.77%7.35%2.3%
3-Month Return-12.29%-0.53%3.8%
6-Month Return-25.47%-1.9%11.11%
1-Year Return-34.8%4.81%22.66%
3-Year Return-34.05%12.27%33.77%
5-Year Return-19.8%45.64%83.8%
10-Year Return198.37%112.69%202.43%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue289.59M543.00K913.08M436.00K371.21M[{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":40.65,"profit":true}]
Cost of Revenue179.36M269.41M101.18M110.25M130.25M[{"date":"2019-12-31","value":66.58,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.56,"profit":true},{"date":"2022-12-31","value":40.92,"profit":true},{"date":"2023-12-31","value":48.35,"profit":true}]
Gross Profit289.59M(268.86M)913.08M(109.81M)240.96M[{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":-29.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.03,"profit":false},{"date":"2023-12-31","value":26.39,"profit":true}]
Gross Margin100.00%(49514.55%)100.00%(25186.70%)64.91%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-49514.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25186.7,"profit":false},{"date":"2023-12-31","value":64.91,"profit":true}]
Operating Expenses242.85M354.98M539.55M563.35M462.29M[{"date":"2019-12-31","value":43.11,"profit":true},{"date":"2020-12-31","value":63.01,"profit":true},{"date":"2021-12-31","value":95.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.06,"profit":true}]
Operating Income46.74M(354.44M)373.53M(673.16M)(222.54M)[{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":-94.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-180.22,"profit":false},{"date":"2023-12-31","value":-59.58,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income67.31M(348.06M)379.53M(650.50M)(150.72M)[{"date":"2019-12-31","value":17.73,"profit":true},{"date":"2020-12-31","value":-91.71,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-171.4,"profit":false},{"date":"2023-12-31","value":-39.71,"profit":false}]
Income Taxes448.00K809.00K1.87M(325.00K)2.89M[{"date":"2019-12-31","value":15.51,"profit":true},{"date":"2020-12-31","value":28.01,"profit":true},{"date":"2021-12-31","value":64.75,"profit":true},{"date":"2022-12-31","value":-11.25,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations66.86M(348.87M)377.66M(650.17M)(153.61M)[{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income66.86M(348.87M)377.66M(650.17M)(153.61M)[{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}]
EPS (Diluted)0.97(5.27)4.42(8.37)(1.96)[{"date":"2019-12-31","value":21.95,"profit":true},{"date":"2020-12-31","value":-119.23,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-189.37,"profit":false},{"date":"2023-12-31","value":-44.34,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRSP
Cash Ratio 21.55
Current Ratio 21.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRSP
ROA (LTM) -9.57%
ROE (LTM) -13.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRSP
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRSP
Trailing PE NM
Forward PE 23.36
P/S (TTM) 17.34
P/B 1.81
Price/FCF NM
EV/R 9.05
EV/Ebitda 14.16
PEG NM

FAQs

What is Crispr Therapeutics AG share price today?

Crispr Therapeutics AG (CRSP) share price today is $42.04

Can Indians buy Crispr Therapeutics AG shares?

Yes, Indians can buy shares of Crispr Therapeutics AG (CRSP) on Vested. To buy Crispr Therapeutics AG from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Crispr Therapeutics AG be purchased?

Yes, you can purchase fractional shares of Crispr Therapeutics AG (CRSP) via the Vested app. You can start investing in Crispr Therapeutics AG (CRSP) with a minimum investment of $1.

How to invest in Crispr Therapeutics AG shares from India?

You can invest in shares of Crispr Therapeutics AG (CRSP) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRSP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Crispr Therapeutics AG shares
What is Crispr Therapeutics AG 52-week high and low stock price?

The 52-week high price of Crispr Therapeutics AG (CRSP) is $91.1. The 52-week low price of Crispr Therapeutics AG (CRSP) is $36.52.

What is Crispr Therapeutics AG price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Crispr Therapeutics AG (CRSP) is 1.81

What is the Market Cap of Crispr Therapeutics AG?

The market capitalization of Crispr Therapeutics AG (CRSP) is $3.65B

What is Crispr Therapeutics AG’s stock symbol?

The stock symbol (or ticker) of Crispr Therapeutics AG is CRSP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top